Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.

January/February ©PharmaTimes

Related information

Webpage

Decentralised & hybrid clinical trials

Whitepaper

Practical considerations in transitioning to hybrid or decentralised clinical trials

Webpage

Decentralised and hybrid trials - The patient perspective

Webpage

Decentralised & hybrid clinical solutions